Select Page
FDA Grants Second Approval for Gilead’s Trodelvy

FDA Grants Second Approval for Gilead’s Trodelvy

The U.S. Food and Drug Administration (FDA) granted accelerated approval for Trodelvy, a drug therapy for patients with locally advanced or metastatic urothelial cancer (mUC), an aggressive disease with a survival rate of 5.5%. Previously, Trodelvy was granted...
Merck Granted Label Expansion by FDA for Keytruda

Merck Granted Label Expansion by FDA for Keytruda

Keytruda, Merck’s checkpoint inhibitor, has been granted label expansion by the U.S. Food and Drug Administration (FDA) for first-line treatment for patients diagnosed with, regardless of PD-L1 expression, locally advanced or metastatic gastroesophageal or...